Tiziana Life Sciences Ltd. (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced acceptance of a publication, “Nasal Administration of anti-CD3 monoclonal antibody (mAb) ameliorates disease in a mouse model of Alzheimer’s disease”, in the preeminent journal, Proceedings of the National Academy of Sciences (PNAS), that supports foralumab’s mechanism as a potential treatment for Alzheimer’s disease (AD), a difficult-to-treat neuroinflammatory disease.
Scientists at St. Jude Children’s Research Hospital found that a subset of CD8+ T cells in the brain lessens the activation of microglia and limits disease pathology in a model of Alzheimer’s disease.
A groundbreaking study led by experts from Indiana University School of Medicine has shed new light on the genetic underpinnings of Alzheimer's disease.
Following more than seven years of research, researchers at the University of Seville-IBiS (Institute of Biomedicine of Seville) have identified a new key cell type with a critical role in the developmental processes of memory and learning.
Researchers used visual flickering sensory stimulation to reveal the underlying mechanisms governing microglial morphology and cytokine expression in mice.
Glioblastoma, the most common and deadly form of brain cancer, grows rapidly to invade and destroy healthy brain tissue. The tumor sends out cancerous tendrils into the brain that make surgical tumor removal extremely difficult or impossible.